Evan Schumacher Fund for Rare Cancer Research
Funding Amount
$50,000
Deadline
Deadline not published
Grant Type
Foundation
Deadline history & next window
- Cycle
- Annual
- Tracked since
- April 2026
Source: the cycle recorded on this listing. Confirm dates with the funder.
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Early-stage investigators studying cholangiocarcinoma
Other requirements
- Scientists at established research institutions
- Focus on holistic, cutting-edge research approaches
Overview
Focus: Supports bright young scientists conducting cutting-edge research to identify effective treatments for cholangiocarcinoma.
Geographic Scope: United States
Established: 2016
Total Funding to Date: $200,000 in targeted research grants
Background
Established in honor of Evan Schumacher, a beloved entrepreneur who lost his life to cholangiocarcinoma at age 46 in 2015. Evan's resilience and strength in facing his illness inspired his friends, family, and colleagues to create this fund to honor his legacy and continue his work in finding effective treatments for rare cancers.
About Evan Schumacher: Serial entrepreneur who founded four Internet companies, known for exceptional talent in spotting new trends, incredible people skills, energy, optimism, and ability to engage others. He believed anything could be accomplished with hard work, drive, and faith. Diagnosed with Stage 4 cholangiocarcinoma with lung metastases in 2014 and died 19 months after diagnosis.
Eligibility
- Early-stage investigators studying cholangiocarcinoma
- Scientists at established research institutions
- Focus on holistic, cutting-edge research approaches
Selection Process
Scientific review by TargetCancer Foundation's Scientific Advisory Board
Recent Grant Recipients
- 2025: Nabeel Bardeesy, PhD - Massachusetts General Hospital Cancer Center ($50,000) - Development of a cholangiocarcinoma tumor atlas
- 2022: Nabeel Bardeesy, PhD - Massachusetts General Hospital Cancer Center ($50,000) - Analyzing collections of human cholangiocarcinoma samples
- 2020: Liron Bar-Peled, PhD - Massachusetts General Hospital Cancer Center ($50,000) - Mapping the landscape of protein druggability in cholangiocarcinoma
- 2018: James Cleary, MD and Srivatsan Raghavan, MD, PhD - Dana-Farber Cancer Institute ($50,000) - Building a cholangiocarcinoma research program
Contact Information
Address: TargetCancer Foundation, 955 Massachusetts Ave., #343, Cambridge, MA 02139
How to Apply
Application Process
No specific application details provided on website. Contact TargetCancer Foundation for application procedures and requirements.
Contact Information for Inquiries
- Phone: 617-475-1673 or 617-765-4881
- Address: TargetCancer Foundation, 955 Massachusetts Ave., #343, Cambridge, MA 02139
Donation Methods (if interested in supporting the fund)
- Online donation via website
- Mail: Send check to TargetCancer Foundation, 955 Massachusetts Ave., #343, Cambridge, MA 02139 (note "Schumacher Fund" in memo line)
- Wire transfer
- Securities donations
- Other giving options available upon request
What TargetCancer Foundation Inc actually gave
Source: IRS Form 990, 2024 — the most recent filing with itemized grants
- Grants in 2024
- 1
- Total given
- $25K
- Median grant
- $25K
- By dollars: Massachusetts 100%. Top recipient cities: Boston, MA.
Example grants
Massachusetts General Hospital · Boston, MA
Cancer Center
$25K
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
TargetCancer Foundation Research Grants Program
TargetCancer Foundation Inc
Amount
Varies ($50,000 - $125,000+)
Deadline
Deadline not published
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health
Amount
$50K – $600K
Deadline
October 19, 2026
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $300,000
Deadline
November 10, 2026
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $150,000
Deadline
November 10, 2026
Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
January 11, 2027
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 8, 2027
Ready to apply for Evan Schumacher Fund for Rare Cancer Research?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Evan Schumacher Fund for Rare Cancer Research. Now let's win it.